Results 91 to 100 of about 80,577 (303)
Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation [PDF]
, 2013 Pyoderma gangrenosum (PG) commonly occurs in association with various haematological and inflammatory disorders. We report a new association, a Janus kinase (JAK)2 mutation, in a 63-year-old patient with PG.
Levell, N. J. +2 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet +11 more
wiley +1 more source
Janus kinase inhibition in the treatment of inflammatory bowel disease [PDF]
, 2020 The aim of this thesis was to investigate Janus kinase (JAK) inhibition in the treatment of inflammatory bowel disease (IBD) from a translational perspective, reflecting both on JAK inhibition as a clinical treatment for IBD as well as on JAK inhibition ...
de Vries, L.C.S.
core +2 more sources
Journal of International Medical ResearchObjective This study aimed to investigate the protective effects of β-escin against neuroinflammatory injury and its influence on the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of ...
Duan Yanqin +9 more
doaj +1 more source
Acta Dermato-VenereologicaThe European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup +4 more
doaj +1 more source
Redox regulation of Janus kinase [PDF]
JAK-STAT, 2013 The redox regulation of Janus kinases (JAKs) is a complex subject. Due to other redox-sensitive kinases in the kinome, redox-sensitive phosphatases, and cellular antioxidant systems and reactive oxygen species (ROS) production systems, the net biological outcomes of oxidative stress on JAK-dependent signal transduction vary according to the specific ...
openaire +2 more sources
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib [PDF]
Yingzhi Luo,1,* Jian Wu,2,* Xingyun Zhao,1,* Ping Yang,1 Yunmi Qiu,1 Liming Wu,1 Jianbo Zhong1 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang ...
Qiu Y +6 more
core +1 more source
RORγt‐APCs: The New Masters of Oral Tolerance
Barrier Immunity, EarlyView.ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley +1 more source
BMC Infectious Diseases, 2019 Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj +1 more source
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment [PDF]
, 2013 BackgroundThe Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).ObjectivesTo report haematology data from the phase IIb trial, given the importance of JAK-dependent ...
Valdez, H +10 more
core